0001179110-21-004119.txt : 20210402
0001179110-21-004119.hdr.sgml : 20210402
20210402180025
ACCESSION NUMBER: 0001179110-21-004119
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210401
FILED AS OF DATE: 20210402
DATE AS OF CHANGE: 20210402
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Smith Karen L.
CENTRAL INDEX KEY: 0001639637
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36065
FILM NUMBER: 21803197
MAIL ADDRESS:
STREET 1: C/O JAZZ PHARMACEUTICALS PLC
STREET 2: 5TH FL, WATERLOO EXCHANGE, WATERLOO RD
CITY: DUBLIN L2 4
STATE: L2
ZIP: 0
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACCELERON PHARMA INC
CENTRAL INDEX KEY: 0001280600
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-649-9200
MAIL ADDRESS:
STREET 1: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
edgar.xml
FORM 4 -
X0306
4
2021-04-01
0
0001280600
ACCELERON PHARMA INC
XLRN
0001639637
Smith Karen L.
128 SIDNEY STREET
CAMBRIDGE
MA
02139
1
0
0
0
Common Stock
2021-04-01
4
M
0
5000
35.34
A
9561
D
Common Stock
2021-04-01
4
M
0
1875
41.64
A
11436
D
Common Stock
2021-04-01
4
M
0
2050
52.99
A
13486
D
Common Stock
2021-04-01
4
S
0
1201
134.54
D
12285
D
Common Stock
2021-04-01
4
S
0
2987
136.22
D
9298
D
Common Stock
2021-04-01
4
S
0
3796
136.92
D
5502
D
Common Stock
2021-04-01
4
S
0
941
137.92
D
4561
D
Option to Purchase Common Stock
35.34
2021-04-01
4
M
0
5000
0
D
2027-11-15
Common Stock
5000
15000
D
Option to Purchase Common Stock
41.64
2021-04-01
4
M
0
1875
0
D
2029-01-25
Common Stock
1875
5625
D
Option to Purchase Common Stock
52.99
2021-04-01
4
M
0
2050
0
D
2030-01-22
Common Stock
2050
6135
D
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.10 to $135.05 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.72 to $136.64 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.74 to $137.36 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.77 to $138.16 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4.
The shares of common stock underlying this stock option award vested in equal quarterly installments over the first three years after the grant.
The shares of common stock underlying this stock option award vested in full on the one year anniversary of the grant date.
/s/ Adam M. Veness, as attorney-in-fact for Karen L. Smith
2021-04-02